Effects of a Glycogen Synthase Kinase 3 Inhibitor Tideglusib on Bone Regeneration With Calvarial Defects.
Lektemur Alpan A, Çalişir M, Kizildağ A, Özdede M, Özmen Ö.
J Craniofac Surg · journal article · DOI 10.1097/scs.0000000000006326 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tideglusib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
18 hitsRegulation of the Nrf2 Pathway by Glycogen Synthase Kinase-3β in MPP⁺-Induced Cell Damage.
Armagan G, Sevgili E, Gürkan FT, Köse FA, Bilgiç T, Dagcı T, Saso L.
Molecules · research-article; journal article · DOI 10.3390/molecules24071377GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis.
Hostiuc S, Perlea P, Marinescu M, Dogaroiu C, Drima E.
Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2018.01495Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Matsunaga S, Fujishiro H, Takechi H.
J Alzheimers Dis · meta-analysis; systematic review; journal article · DOI 10.3233/jad-190256Tideglusib Rescues Neurite Pathology of SPG11 iPSC Derived Cortical Neurons.
Pozner T, Schray A, Regensburger M, Lie DC, Schlötzer-Schrehardt U, Winkler J, Turan S, Winner B.
Front Neurosci · research-article; journal article · DOI 10.3389/fnins.2018.00914Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice.
Fuchs C, Fustini N, Trazzi S, Gennaccaro L, Gennaccaro L, Rimondini R, Ciani E.
Eur J Neurosci · research support, non-u.s. gov't; journal article · DOI 10.1111/ejn.13923GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib.
Mathuram TL, Reece LM, Cherian KM.
Drug Res (Stuttg) · review; journal article · DOI 10.1055/s-0044-100186LC-MS/MS determination of tideglusib, a novel GSK-3β inhibitor in mice plasma and its application to a pharmacokinetic study in mice.
Saini NK, Suresh PS, Lella M, Bhamidipati RK, Rajagopal S, Mullangi R.
J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2017.09.022Correlative Studies Unravelling the Possible Mechanism of Cell Death in Tideglusib-Treated Human Ovarian Teratocarcinoma-Derived PA-1 Cells.
Mathuram TL, Ravikumar V, Reece LM, Sasikumar CS, Cherian KM.
J Environ Pathol Toxicol Oncol · journal article · DOI 10.1615/jenvironpatholtoxicoloncol.2017025018Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation.
Mathuram TL, Ravikumar V, Reece LM, Karthik S, Sasikumar CS, Cherian KM.
Environ Toxicol Pharmacol · journal article · DOI 10.1016/j.etap.2016.07.013Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice.
Wang H, Huang S, Yan K, Fang X, Abussaud A, Martinez A, Sun HS, Feng ZP.
Biochim Biophys Acta · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbagen.2016.06.027Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
Anand K, Sabbagh M.
Expert Opin Investig Drugs · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1517/13543784.2015.1075002Tideglusib protects neural stem cells against NMDA receptor overactivation.
Armagan G, Keser A, Atalayın Ç, Dagcı T.
Pharmacol Rep · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pharep.2015.01.007A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T, ARGO investigators.
J Alzheimers Dis · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.3233/jad-141959A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.
Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T, TAUROS Investigators.
Mov Disord · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/mds.25824Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.
Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T, TAUROS MRI Investigators.
Mov Disord · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/mds.25815Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.
del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T.
J Alzheimers Dis · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.3233/jad-2012-120805NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders.
Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A.
J Neurosci · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1523/jneurosci.1004-07.2007